Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology

Miroslav Pohanka

Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 50001 Hradec Kralove, Czech Republic; E-Mail: miroslav.pohanka@gmail.com; Tel.: +420-973253091; Fax: +420-973253091.

Received: 16 January 2012; in revised form: 26 January 2012 / Accepted: 14 February 2012 / Published: 17 February 2012

Abstract: Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an important part of the cholinergic nerve system in the brain. Moreover, it is associated with a cholinergic anti-inflammatory pathway in the termination of the parasympathetic nervous system. Antagonists of α7 nAChR are a wide group represented by conotoxin and bungarotoxin. Even Alzheimer’s disease drug memantine acting as an antagonist in its side pathway belongs in this group. Agonists of α7 nAChR are suitable for treatment of multiple cognitive dysfunctions such as Alzheimer’s disease or schizophrenia. Inflammation or even sepsis can be ameliorated by the agonistic acting compounds. Preparations RG3487, SEN34625/WYE-103914, SEN12333, ABT-107, Clozapine, GTS-21, CNI-1493, and AR-R17779 are representative examples of the novel compounds with affinity toward the α7 nAChR. Pharmacological, toxicological, and medicinal significance of α7 nAChR are discussed throughout this paper.

Keywords: inflammation; cholinergic anti-inflammatory pathway; schizophrenia; Alzheimer’s disease; cognitive disorder; agonist; antagonist

1. Introduction

Pharmacological neuromodulation has become one of the suitable tools for influencing the whole system of the human body. However, the interest in this is undermined by the fact that drugs specifically implicated in neuromodulation will be more potent than the ones influencing the periphery
due to their effect amplification. Nevertheless, the current attention is aimed at the treatment of illnesses associated with neuropathology e.g., schizophrenia, Alzheimer’s and Parkinson disease.

Because the nerve system is connected with many processes, the neuromodulation can be used for alteration of, e.g., the immune system or to slow down degenerating processes. This review is focused on α7 nicotinic acetylcholine receptor as a pharmacological target. The receptor is well known for its role in the central nervous system but only recently a connection of the immune system and parasympathetic nervous system was recognized. Future perspectives are introduced here.

2. Acetylcholine as Neurotransmitter

The cholinergic system is one of the excitatory pathways participating in the parasympathicus, sympathetic, and the central nervous system using acetylcholine as a neurotransmitter [1]. Loewi was the first investigator that proposed the physiological importance of the simple compound acetylcholine in the 1920s [2]. Acetylcholine and acetylcholine receptors are known to be present on many cell types including endothelial cells and cells of the immune system [3].

Acetylcholine is synthesized from two precursors: acetyl coenzyme A and choline using enzyme choline O-acetyltransferase (ChAT; EC 2.3.1.6). ChAT with higher activity is localized in cytosol near neurosynapses as a soluble molecule. However, ChAT can be also found as a membrane bound structure [4]. The localization of ChAT in neurons by immunohistopathology is a basic tool for distinguishing between cholinergic and adrenergic nerve system [5]. Acetylcholine established in neurons is antiported by protons into vesicles using vesicular acetylcholine transporter (VACHT). Interaction of vesicles with the neurosynapse membrane is possible only if change in calcium level inside the cell takes place. The process is assisted by vesicle-associated membrane proteins (VAMP). The absorbed calcium molecules interact with C2A and C2B subunits of synaptotagmin [6]. Synaptoprevin in the presence of calcium forms a complex with synaptoosomal-associated protein 25 (SNAP-25) which is weakly bound on the inner membrane of synapse [7]. Subsequently, syntaxin, another molecule on the inner membrane undergoes interaction with the complex resulting in the final formation of a complex soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptors (SNARE) necessary for acetylcholine vesicles fusion with membrane [8]. Acetylcholine is released by fusion of the vesicles and cell membranes and interacts with acetylcholine receptors (AChR).

Acetylcholine is a chemically stable compound that can persist for a long time after spreading into the neurosynaptic cleft and spontaneous elimination is slow due to the quaternary ammonium atom in the choline moiety. For this reason, enzyme acetylcholinesterase (AChE) is present in the neurosynaptic cleft to quickly terminate the signal. AChE splits acetylcholine into acetic acid and choline [9] while choline is transported from the neurosynaptic cleft using high-affinity choline transporter (ChT) back to the cytosol, acetic acid is further decomposed [10]. The complete scheme of cholinergic neurotransmission is depicted in Figure 1.

In addition to AChRs and AChE, other proteins related to vesicles fusion are also targets of numerous toxins e.g., butulotoxins. These endopeptidases are produced by bacteria *Clostridium botulinum* and less commonly by *C. baratii* and *C. butyricum* [11,12]. Butulotoxin is a dimer composed of 100 kDa heavy chain and 50 kDa light chain with Zn^{II} endopeptidase activity [13]. There are seven basic isoforms of butulotoxine (A, B, C, D, E, F, and G) with different substrate
selectivity [14]. A, C and E split SNAP 25 while B, D, F and G split synaptobrevin. The last type C splits syntaxin.

**Figure 1.** Overview of cholinergic neurotransmission: ACh—acetylcholine; Ac—acetate; AChE—acetylcholinesterase; AChR—acetylcholine receptor; ChAT—choline O-acetyltransferase; ChT—high-affinity choline transporter; VAcH—vesicular acetylcholine transporter, 1—axonal termination of neuron; 2—dendrite of neuron or other target cell.

3. Acetylcholine Receptors

Two types of AChRs are known: muscarinic (mAChR) and nicotinic (nAChR). Names are derived from responses to interactions with secondary metabolites recognized as selective agonists. Muscarine is a fungal natural parasympathomimetic from the fly amanita (*Amanita muscaria*). The mAChRs can be found in the central as well as peripheral nervous system. In an extensive level it is inherent in the neuromuscular junction and endocrine glands. In comparison with nAChR, mAChR are coupled with G proteins [15]. In compliance with the former approach, mAChRs were divided into two separate groups: the first was stimulatory, connected with the activity of phospholipase C, the second type is inhibitory based on the suppression of adenylate cyclase activity [16]. Five types of mAChRs are currently known: M1, M2, M3, M4 and M5 [17]. The types M1, M3, and M5 are connected with the accumulation of intracellular calcium and activation of phospholipases. The preference junction of the M1, M3 and M5 is toward Gq and Gi1 [18,19]. The last subtypes M2 and M4 inhibit adenylate cyclase via Gi or Gz [20,21]. Atropine is a known secondary metabolite from solanum plants (*Solanaceae*) and is probably the best-known antagonist of acetylcholine on mAChR. Atropine is widely used for the treatment of bradycardia and asystole [22] and can also protect mAChR from overstimulation when AChE becomes inhibited e.g., by nerve agents [23]. Scopolamine is another antagonist of M1 receptors.
used in ophthalmology and for suppression of nausea [24]. Modulation of mAChR can be also suitable for the treatment of psychotic disorders [25]. Stimulation of M1 and M4 can suppress effect of amphetamines [26] and stimulation of M1 is perspective in the development of drugs for schizophrenia treatment [27]. Combination of M1 agonists and AChE inhibitors promotes REM sleep [28].

Nicotinic acetylcholine receptors (nAChR) are named after natural agonist nicotine, a secondary metabolite from a common tobacco plant (Nicotiana tabacum, Solanaceae). Nicotine alone is used to wean patients from smoking and in combination with other ingredients of cigarette smoke reduces schizophrenia manifestations [29,30]. However, it is unclear whether nicotine influences cognitive functions during schizophrenia by nAChR agonism or if it is implicated in monoamine oxidase activity modulation [31]. Currently, clinical trials are conducted to confirm nicotine’s benefits to patients with Parkinson’s disease, schizophrenia, sarcoidosis, and as pain relief [32]. It is widely accepted that nAChRs are present in both central and peripheral sections of the nerve system and neuromuscular junctions. In addition, evidence suggests nicotine also participates in the nerve-immune system junction [33] as introduced later.

In mammals, analysis of cDNA proved existence of 17 homologues of nAChR’s subunits divided into five subtypes: α1-10, β1-4, γ, δ, ε [34]. Except of the avian subtype α8, all subtypes can be found in mammals [35]. One nAChR molecule is composed from five subunits formed in radial symmetry with central pore. Each subunit includes four transmembrane α helixes, large intracellular domain composed from one α helix and extracellular part with affinity to acetylcholine and other agonists [36]. Acetylcholine is bound in a cavity formed by the disulfide bridge from the two cysteine residues. From the known subtypes, the cavity is formed by α1, α2, α3, α4, α6, α7 and α8 subtypes only. The other subtypes, α1, β2, β4, δ, γ and ε, may stabilize cavity from the outside [37]. Homopentamer α7 as well as some other receptors have the affinity not only to acetylcholine but also to choline [38]. The individual subtypes can be combined one to each other with different steciometry. The (α7)5, (α4)2(β2)3, (α4)3(β2)2 a (α4)2(β2)2 α5 nAChR are the most common [39,40]. Mechanism of the nAChR’s function is the same for all receptors regardless to presence of different subtypes. It forms an ion channel every time. However, the main difference is in which ions are allowed to flow through the receptor. The presence of polar regions and/or subtype α3 will allow selective flow of Na⁺ and K⁺. On the other hand, non-polar residua and a high level of glutamic acid typical for the α7 nAChR homopentamer, enhance specificity to Ca²⁺ [41].

nAChRs are influenced by several toxins and pharmacologically applicable compounds e.g., α bungarotoxin from the Taiwan krait Bungarus multicinctus. It is a strong antagonist of nAChRs with partial selectivity to α7 nAChR [42]. nAChRs are considered to be a strong antagonist on succinylcholine (suxamethonium), they are used for recovery from near fatal hyperthermia [43] and neuromuscular junction paralysis in anesthesia [44]. Since succinylcholine is converted by plasmatic butyrylcholinesterase, butyrylcholinesterase dysfunctional patients are extremely sensitive to succinylcholine and recovery from its application lasts longer when compared to individuals with fully active butyrylcholinesterase [45].
4. α7 Nicotinic Acetylcholine Receptor in Brain

The α7 nAChR is implicated in cognitive functions of the central nervous system. Modulation of α7 nAChR is considered to be perspective for the treatment of cognitive disorders such as Alzheimer’s disease or schizophrenia. Agonists of α7 nAChR are able to penetrate through the blood brain barrier. They are objects of pharmacologists’ interest as they are suitable for cognitive function amelioration in patients suffering from Alzheimer’s disease and schizophrenia [46]. Moreover, amyloid β released in Alzheimer’s disease patients also extensively binds to the brain α7 nAChR and prevents its natural function [47]. As acetylcholine level is limited in Alzheimer’s disease damaged brain agonizing α7 nAChR is considered as a promising way to enhance cognitive functions [48]. Feher et al. investigated the link between α7 nAChR and some types of dementia [49]. They recognized significantly elevated 2 bp deletion in α7 nAChR subunit gene in individuals suffering from Alzheimer’s disease, dementia with Lewy bodies, and Pick’s disease. Moreover, actual α7 nAChR is over-expressed in patients with Alzheimer’s disease [50]. These findings should be extensively researched and molecular mechanism of α7 nAChR in neurodementias has to be better understood before any conclusions can be made.

Experimental application of α7 nAChR agonists can be beneficial in schizophrenia treatment e.g., Tregellas et al. successfully tested 3-(2,4-dimethoxybenzylidene) anabaseine as a α7 nAChR agonist [51]. It is vital that cholinergic nerves can modulate release of dopamine and glutamate. Livingston et al. proved that α7 nAChR might be stimulated by choline. Moreover, they tested compound PNU-120596 (see later) and proved that it elicits dopamine release in the rat prefrontal cortex [52]. Effectiveness of α7 nAChRs agonists is intriguing for schizophrenia treatment. Drugs for schizophrenia Clozapine and 3-(2,4-dimethoxybenzylidene) anabaseine can be used as an example of drugs implicated in α7 nAChR agonism [53]. Special animal models have been introduced in order to investigate the α7 nAChR modulation by chemical compounds for, e.g., Alzheimer’s disease and other disorders [54–56].

5. Cholinergic Anti-Inflammatory Pathway

Cholinergic anti-inflammatory pathway is a link between parasympathetic and innate immune system. Tracey and co-workers firstly described it as they recognized nervus vagus in immunomodulation and called it inflammatory reflex [57]. Scheme of cholinergic anti-inflammatory pathway is depicted as Figure 2. Macrophages are able to produce pro-inflammatory cytokines e.g., tumor necrosis factor α (TNFα) and expression of high-mobility group protein 1 (HMG 1) with intracellular as well as extracellular signalization function. Regarding cholinergic anti-inflammatory pathway, principal parasympathetic terminations in the blood system are able to release acetylcholine that interacts with α7 nAChR on macrophages surface. Macrophage-assisted inflammation is stopped after the receptor stimulation. During inflammation the α7 nAChR action is associated with calcium influx and stop of nuclear factor κB (NF κB) stimulation [58–60].

Inflammatory processes can be deteriorating without being properly controlled. Septic shock can be mentioned as an example. It is a life-threatening event with high expected mortality rate [61]. Another deteriorating action of immune system represented by macrophages is atherosclerosis [62]. Macrophages are also a target in HIV pathology as virus can proliferate within and the pathology is
also involved in macrophage mediated bystander T lymphocytes apoptosis [63]. Stimulation of the cholinergic anti-inflammatory pathway is believed to be a neuro-immunomodulatory action with fast and reliable calming of the innate immune system [64]. The cholinergic anti-inflammatory pathway was proven to be effective in sepsis treatment [65], in ischemia (myocardial ischemia reperfusion injury) [66], and rheumatoid arthritis [67].

**Figure 2.** Scheme of cholinergic anti-inflammatory pathway: ACh—acetylcholine; TNF α—tumor necrosis factor α; HMG 1—high-mobility group protein 1.

6. Antagonists of α7 nAChR

Agonists and antagonists of α7 nAChR are a wide group of heterogeneous compounds. Antagonists of α7 nAChR have lower practical impact in comparison with agonists. Several natural toxins can be used as examples of compounds antagonizing acetylcholine on α7 nAChR [32]. Moreover, some drugs are potent to antagonize α7 nAChR as a side effect of their main pharmacological effect. Two groups of proteins’ respective peptides are the best-known antagonists of α7 nAChR. Conotoxins are a group of cysteine-rich peptides from cone snails (Conus sp.) possessing various ion channel blocking. The α conotoxins selectively target the nAChR [68]. They contain two-loop frameworks and are selective to the acetylcholine binding site [69]. α conotoxins from cone snail Conus consors abbreviated as CnIA with sequency GRCCCHPACGKYYSC and amidated C terminus are selective and reversible antagonists of α7 nAChR [70]. However, the other α conotoxins such as α conotoxin PnIA are also antagonists of α7 nAChR with low median inhibitory concentration: 14 nM [71]. Conotoxins are potent inhibitors of nAChR when considered the median inhibitory concentration for the individual toxins. The strongest inhibitors possess median inhibitory concentration in nanomolar levels [72]. Due to their size and physical properties, conotoxins cannot simply cross the blood brain barrier. Thereby their action is preferably in the peripheral nervous system [73]. On the other hand, distribution to the central nervous system is not restricted and central action of conotoxins can be also recognized in
some cases [74]. Though the conotoxins are not utilized for pharmacology purposes, they were found to be suitable for distinguishing between individual types of nAChR [75].

α Bungarotoxin is another specific antagonist of α7 nAChR. It is venom from Taiwanese krait Bungarus multicinctus. Beside α7 nAChR, α bungarotoxin can also bind on to GABA β3 subunit [76]. The isolation of α Bungarotoxin and understanding mechanism of action has been extensively investigated from 1960s [77,78]. α Bungarotoxin binds irreversibly to the nAChR and the complex bungarotoxin—nAChR is immunogenic, which may result in production of autoimmune antibodies. For this reason, α bungarotoxin is a suitable experimental model for myasthenia gravis [79].

Memantine (3,5-Dimethyl-tricyclo[3.3.1.1^3,7]decan-1-amine hydrochloride) and methyllycaconitine are low molecular weight antagonists of α7 nAChR. Memantine (Figure 3) is an approved drug for treatment of Alzheimer's disease acting as a strong NMDA receptor antagonist. Beside the action on NMDA receptors, memantine was proved to be a α7 nAChR antagonist with median inhibitory concentration 0.34 µM [80]. Although Aracava et al. considered antagonism of memantine on α7 nAChR as a negative phenomenon in Alzheimer's disease treatment [80], the antagonism is considered to be beneficial in Alzheimer's disease treatment according to other scientists [81]. However, the significance of the antagonism should be elucidated and antagonism suitability for Alzheimer's disease treatment is not a common view; more trials are needed [82]. Methyllycaconitine is a 683 Da weighting secondary metabolite from Consolida genus. It is an antagonist of nAChR with the highest affinity to α7 subtype [83,84]. However, there still remains one group of nAChR antagonists that were not mentioned in the previous text: pyridinium oximes and bispyridinium oximes. These compounds are used for antidotal treatment after exposure to organophosphorous inhibitors of AChE [85]. It was proved that these compounds can bind like acetylcholine due to the quarternary ammonium atom and interact with AChE and with AChR [86,87]. Biological effects HI-6 (asoaxime; Figure 3) are considered to be associated with α7 nAChR; unfortunately the plausible proof is still missing [88,89]. The antagonists of α7 nAChR are summarized in Table 1.

Figure 3. Structures of memantine and HI-6.
Table 1. Overview of selected α7 nAChR antagonists.

| Name                  | Structure                                                                 | Source                      | Use                                                  | Reference |
|----------------------|---------------------------------------------------------------------------|-----------------------------|------------------------------------------------------|-----------|
| α-bungarotoxin       | 8 kDa globular protein                                                    | Taiwanese krait Bungarus multicinctus | not used in therapy, natural toxin                   | [77–79]   |
| CnIA, PnIA polypeptide | α-conotoxins from cone snail Conus consors                               | natural toxin, use in research for distinguishing of acetylcholine receptors types | [70–75]   |
| HI-6 (also known as asoxime) | 1-[(4-carbamoylpyridin-1-ium-1-yl)methoxymethyl]pyridin-1-ium-4-carboxamide dichloride CAS: 34433-31-3 | therapy of nerve agents poisoning via reactivation of AChE | [85–89]   |
| memantine            | 3,5-Dimethyltricyclo[3.3.1.13,7]decan-1-amine hydrochloride CAS: 19982-08-2 | adamantane derivative       | Alzheimer’s disease drug antagonizing NMDA receptor, antagonism of α7 nAChR is a side pathway | [80–82]   |
| methylcaconitine     | 683 Da alkaloid Consolida flowers                                         | not used in therapy, natural toxin | [83–84]   |

7. Agonists of α7 nAChR

α7 nAChR agonists become a group of extensively investigated compounds. As was mentioned above, agonists are perspective for the treatment of cognitive dementia, schizophrenia, inflammation and sepsis regarding to the physiological importance of α7 nAChR. However, structural requirements for these drugs are quite different. Drugs suitable for schizophrenia and dementia treatments have to be able to penetrate the blood brain barrier. On the other hand, the cholinergic anti-inflammatory pathway can be also be controlled by compounds that are not distributed into the central nervous system. The blood brain barrier penetrating compounds are typically small lipophilic molecules with no charged atom [90,91] and/or recognizable by specific carriers [92]. Piperidyl or azabicyclooctane derivatives are the most common derivatives.
Selected pharmacologically relevant agonists of α7 nAChR are depicted in Figure 4. Wallace et al. prepared compound RG3487, N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-1H-indazole-3-carboxamide hydrochloride recognized as a human α7 nAChR agonist with high affinity represented by equilibrium constant 6 nM and median effective concentration 0.8 µM [93]. RG3487 was also proved as a potent antagonist of serotonin receptor with median inhibitory constant 2.8–33 nM. The authors proved the significant effect of the compound on rodents’ cognitive functions and discussed perspectives for Alzheimer’s disease symptomatic treatment. Moreover, it was proven to reverse phencyclidine-induced...
impairments in a rodent model. Another agonist of \( \alpha_7 \) nAChR for cognitive disorders treatment was introduced by Chiron et al. [94]. They introduced 1-[6-(4-fluorophenyl) pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea, abbreviated as SEN34625/WYE-103914, that is a strong agonist of \( \alpha_7 \) nAChR as the median effective concentration was 70 nM. SEN34625/WYE-103914 is the more effective analogue of previously prepared compound SEN12333 (5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide) promising for Alzheimer’s disease and schizophrenia treatment with median effective concentration to \( \alpha_7 \) nAChR 12 \( \mu \)M [95]. The compound crosses the blood brain barrier well and can be administered orally. ABT-107 is also an agonist of \( \alpha_7 \) nAChR structurally different to SEN compounds [96]. Median effective concentration for ABT-107 was 50–90 nM for rat oocytes. According to the author’s report, ABT-107 was also found to be effective in protecting rat cortical cultures from glutamate-induced toxicity. In the text above, clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[\( \text{b,e} \)][1,4]diazepine) and 3-(2,4-dimethoxybenzylidene) anabaseine were mentioned as drugs acting as a \( \alpha_7 \) nAChR agonists [51,53]. However, clozapine is a commercial antipsychotic for schizophrenia [97] and interaction with \( \alpha_7 \) nAChR is not the main pharmacological pathway. It is sold under different trade names e.g., Azaleptin, Clozaril, FazaClo, Leonex and others. Besides those mentioned above, some other compounds are in clinical trials and are at the center of extensive scientific interest. PNU-120596 (1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea) is a potent allosteric modulator [98] with good potential to act as a neuroprotective agent enhancing cognition ability [99]. Compound TC-5214 (S-\((+\))-mecamylamine) is nAChR antagonist with low selectivity toward individual isotypes [100]. Presently, the TC-5214 preparation is evaluated for its palliative and antidepressant effect. Promising compounds acting as a \( \alpha_7 \) nAChR selective agonists seem to be also AZD0328 and TC-5619, both containing azabicyclocloctane group. They are expected to be useful to treating multiple cognitive dysfunctions and schizophrenia [101,102]. It is noteworthy that product of acetylcholine hydrolysis, choline, is an agonist of \( \alpha_7 \) nAChR, too [103].

Compounds eliciting cholinergic anti-inflammatory pathway are another group of promising drugs. Immunology principle of the cholinergic anti-inflammatory pathway was extensively reviewed recently [64,104]. Pharmacological stimulation of the pathway seems to be suitable for treatment of multiple diseases associated with over stimulation of immune system such as autoimmune disorders, sepsis, acute pancreatitis etc. [105,106]. Presently, there is no clinically approved drug primary targeted on cholinergic anti-inflammatory pathway. However, certain novel compounds seem to be promising for the pertinent clinical trials. An example is \( [3-(2,4-dimethoxybenzylidene) \text{anabaseine}] \) abbreviated as GTS-21 or DMXB-A in some sources. It is a compound found in Pacific nemertine \( \text{Paranemertes peregrina} \) and currently tested for treatment of Alzheimer’s disease and cognitive deficits associated with schizophrenia [107]. It is able to attenuate TNF \( \alpha \) as well as other pro-inflammatory cytokines production. GTS-21 (Figure 5) was able to improve survival rate of BALB/c mice suffered from endotoxemia when applied in dose 4 mg/kg [108]. As proved on a C57BL/6 mouse model, the compound is also suitable for prevention of inflammatory injury induced by mechanical ventilation [109]. In addition to the anti-inflammatory pathway, GTS-21 was assessed in a clinical trial and was proved to improve the cognitive functions of schizophrenic patients [110]. A tertravalent guanylhydrazone CNI-1493 (Figure 5) known also as semapimod (\( N,N'\)-bis[3,5-bis[\( N\)-(diaminomethylideneamino)-C-methylcarbonimidoyl] phenyl] decanediame tetrahydrochloride) is an agonist of \( \alpha_7 \) nAChR primary introduced as a selective pro-inflammatory cytokine inhibitor [111]
suitable for activation of cholinergic anti-inflammatory pathway [112]. In addition to this, it
ameliorates amyloid β deposition and it is a perspective for treatment of cognitive deterioration in
Alzheimer’s disease. It acts via suppression of inflammation with perspective to amend disease
progression [113]. CNI-1493 was found to be effective for resolving of endotoxic shock in a rat model
[114]. In a clinical trial, CNI-1493 was examined as a drug for the treatment of Crohn’s disease [115],
a disease associated with inflammation. The investigators reported no plausible effect for CNI-1493
single and 3 day dosing. However, cumulative dosing brings some positive effects to Crohn’s disease
therapy. Anti-inflammatory properties were also found for a α7 nAChR agonist AR-R17779 ((2S)-
2’H-spiro[4-azabicyclo[2.2.2]octane-2,5’-[1,3]oxazolidin]-2’-one) which is reported to be suitable for
amelioration of ileus in mice [116]. AR-R17779 (Figure 5) can also act in the central nervous system
where it can ameliorate cognitive function [117]. Selected α7 nAChR antagonists are summarized in
Table 2.

Figure 5. Structures of α7 nAChR agonists with significant anti-inflammatory properties.
Table 2. Overview of selected α7 nAChR antagonists.

| Name               | Structure                                                                 | Use                                                                 | Reference         |
|--------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------|-------------------|
| ABT-107            | 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl]-1H-indole       | Treatment of Alzheimer’s disease and cognitive deficits associated with schizophrenia, under testing, not commercially available | [96]              |
| SEN12333           | 5-morpholin-4-yl-pentanoic acid (4-pyridin-3-yl-phenyl)-amide             |                                                                      | [95]              |
| TC-5619            | \(N\)-[(2S,3S)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide |                                                                      | [102]             |
| Clozapine          | 8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine         | Commercially available drug (trade names Azaleptin, Clozaril, FazaClo, Leonex and others), used as antipsychotics in paranoid disorders and schizophrenia | [51,53]          |
| CNI-1493           | \(N,N^\prime\)-bis[3,5-bis[(diaminomethylideneamino)-C-methylcarbonimido]ylphenyl] decanediamide tetrahydrochloride | Inhibitor of inflammation and NO production, antagonist of α7 nAChR via cholinergic anti-inflammatory pahtway, known as a drug Semapimod, under clinical trials | [112–115]        |
| GTS-21 (or DMXB-A) | 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl] pyridine | Treatment of Alzheimer’s disease and cognitive deficits associated with schizophrenia, experimental testing for anti-inflammatory potency, under clinical testing | [107–110]        |

8. Conclusions

Agonists and antagonists of α7 nAChR are pharmacologically relevant compounds suitable for treatments of multiple cognitive dysfunctions and/or inflammation associated diseases. Although drugs specifically targeted to α7 nAChR are not clinically approved, the recent investigations provided good preliminary results. In compliance with the known facts about novel compounds, increased clinical interest and clinical trials for the novel drugs can be expected.

Acknowledgments

Institutional research: Funds for organization development (Ministry of Education, Youth and Sport of Czech Republic) is gratefully acknowledged.

References

1. Rand, J.B. Acetylcholine. *WormBook* 2007, doi:10.1895/wormbook.1.131.1. Available online: http://www.wormbook.org (accessed on 17 February 2012).
2. Loewi, O. Uberhumerole ubertragbarkeit der herznervenwirkung. *I. Mitt. Pflugers Arch.* **1921**, *189*, 239–242.
3. Wessler, I.; Kirkpatrick, C.J. Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans. *Br. J. Pharmacol.* **2008**, *154*, 1558–1571.

4. Gabrielle, P.; Jeana, M.; Lorenza, E.C. Cytosolic choline acetyltransferase binds specifically to cholinergic plasma membrane of rat brain synaptosomes to generate membrane-bound enzyme. *Neurochem. Res.* **2003**, *28*, 543–549.

5. Phillis, J.W. Acetylcholine release from the central nervous system: A 50year retrospective. *Crit. Rev. Neurobiol.* **2005**, *17*, 161–217.

6. Llona, I. Synaptic like microvesicles: Do they participate in regulated exocytosis? *Neurochem. Int.* **1995**, *27*, 219–226.

7. Dun, A.R.; Rickman, C.; Duncan, R.R. The t-SNARE complex: A close up. *Cell Mol. Neurobiol.* **2010**, *30*, 1321–1326.

8. Snyder, D.A.; Kelly, M.L.; Woodbury, D.J. SNARE complex regulation by phosphorylation. *Cell Biochem. Biophys.* **2006**, *45*, 111–123.

9. Rotundo, R.L. Expression and localization of acetylcholinesterase at the neuromuscular junction. *J. Neurocytol.* **2003**, *32*, 743–766.

10. Sarter, M.; Parikh, V. Choline transporters, cholinergic transmission and cognition. *Nat. Rev. Neurosci.* **2005**, *6*, 48–56.

11. Hall, J.D.; McCroskey, L.M.; Pincomb, B.J.; Hatheway, C.L. Isolation of an organism resembling Clostridium baratii which produces type F botulinial toxon from an infant with botulism. *J. Clin. Microbiol.* **1985**, *21*, 654–655.

12. Aureli, P.; Fenicia, L.; Pasolini, B.; Gianfranceschi, M.; McCroskey, J.M.; Hatheway, C.L. Two cases of type infant botulism caused by neurotoxigenic clostridium butyricum in Italy. *J. Infect. Dis.* **1986**, *154*, 207–211.

13. Lacy, D.B.; Tepp, W.; Cohen, A.C.; DasGupta, B.R.; Stevens, R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. *Nat. Struct. Biol.* **1998**, *5*, 898–902.

14. Singh, B.R. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. *Neurotox. Res.* **2006**, *9*, 73–92.

15. Hirota, S.A. A quick guide to muscarinic acetylcholine receptors. *BioPharm. J.* **2001**, *5*, 6–8.

16. Felder, C.C. Muscarinic acetylcholine receptors: Signal transduction through multiple effectors. *FASEB J.* **1995**, *9*, 619–625.

17. Tobin, G.; Giglio, D.; Lundgren, O. Muscarinic receptor subtypes in the alimentary track. *J. Physiol. Pharmacol.* **2009**, *60*, 3–21.

18. Berstein, G.; Blank, J.L.; Smrcka, A.; Higashijima, T.; Sternweis, P.C.; Exton, J.H.; Ross, E.M. Reconstitution of agonist-stimulated phosphatidylinositol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor, G, and phospholipase C-β1. *J. Biol. Chem.* **1992**, *267*, 8081–8088.

19. Falkenburger, B.H.; Jensen, J.B.; Hille, B. Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells. *J. Gen. Physiol.* **2010**, *135*, 81–97.

20. Parker, E.M.; Kameyama, K.; Higashijima, T.; Ross, E.M. Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells. *J. Biol. Chem.* **1991**, *266*, 519–527.
21. Alfonzo, M.J.; de Becemberg, I.L.; de Villaroel, S.S.; de Herrerea, V.N.; Misle, A.J.; de Alfonzo, R.G. Two opposite signal transducing mechanisms regulate a G-protein-coupled guanylyl cyclase. *Arch. Biochem. Biophys.* 1998, 350, 19–25.

22. Horng, H.C.; Chen, F.C.; Ho, C.C.; Kuo, C.P.; Wu, C.T.; Wong, C.S. Bradycardia and hypotension refractory to ephedrine and atropine treatment: Severe autonomic dysfunction with abnormal heart rate variability. *Acta Anaesthesiol. Taiwan* 2006, 44, 109–112.

23. Bryant, S.M.; Rhee, J.W.; Thompson, T.M.; Aks, S.E. Pretreating rats with parenteral ophthalmic antimuscarinic agents decreases mortality from lethal organophosphate poisoning. *Acad. Emerg. Med.* 2007, 14, 370–372.

24. Nachum, Z.; Shupak, A.; Gordon, C.R. Transdermal scopolamine for prevention of motion sickness: Clinical pharmacokinetics and therapeutic applications. *Clin. Pharmacokinet.* 2006, 45, 543–566.

25. Bridges, T.M.; Lebois, E.P.; Hopkins, C.R.; Wood, M.R.; Jones, C.K.; Conn, P.J.; Lindsley, C.W. The antipsychotic potential of muscarinic allosteric modulation. *Drug News Perspect.* 2010, 23, 229–240.

26. Woolley, M.L.; Carter, H.J.; Gartlon, J.E.; Watson, J.M.; Dawson, L.A. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 redceptor knockout mice. *Eur. J. Pharmacol.* 2009, 603, 147–149.

27. Sellin, A.K.; Shad, M.; Tamminga, C. Muscarinic agonists for the treatment of cognition in schizophrenia. *CNS Spectr.* 2008, 13, 985–996.

28. Nissen, C.; Nofzinger, E.A.; Feige, B.; Waldheim, B.; Radosa, M.P.; Riemann, D.; Berger, M. Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. *Neuropsychopharmacology* 2006, 31, 1294–1300.

29. Winterer, G. Why do patients with schizophrenia smoke. *Curr. Opin. Psychiatry* 2010, 23, 112–119.

30. Williams, J.M.; Gandhi, K.K. Use of caffeine and nicotine in people with schizophrenia. *Curr. Drug Abuse Rev.* 2008, 1, 155–161.

31. Rommelspacher, H.; Meier-Henco, M.; Smolka, M.; Kloft, C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. *Eur. J. Pharmacol.* 2002, 441, 115–125.

32. Nasiripourdori, A.; Taly, V.; Grutter, T.; Taly, A. From toxins targeting ligand gated ion channels to therapeutic molecules. *Toxins* 2011, 3, 260–293.

33. Tracey, K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. *J. Clin. Invest.* 2007, 117, 289–296.

34. Millar, N.S. A review of experimental techniques used for the heterologous expression of nicotinic acetylcholine receptors. *Biochem. Pharmacol.* 2009, 78, 766–776.

35. Lohmann, T.H.; Torrao, A.S.; Britto, L.R.; Lindstrom, J.; Hamassaki-Britto, D.E. A comparative non-radioactive in situ hybridization and immunohistochemical study of the distribution of alpha7 and alpha8 subunits of the nicotinic acetylcholine receptors in visual areas of the chick brain. *Brain Res.* 2000, 852, 463–469.
36. Unwin, N. Refined Structure of the nicotinic acetylcholine receptor at 4 Å resolution. *J. Mol. Biol.* 2005, 346, 967–989.

37. Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: From structure to function. *Physiol. Rev.* 2009, 89, 73–120.

38. Alkondon, M.; Pereira, E.F.R.; Cortes, W.S.; Maelicke, A.; Albuquerque, E.X. Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons. *Eur. J. Neurosci.* 1997, 9, 2734–2742.

39. Zhou, Y.; Nelson, M.E.; Kuryatov, A.; Choi, C.; Cooper, J.; Lindstrom, J. Human α4β2 acetylcholine receptors formed from linked subunits. *J. Neurosci.* 2003, 23, 9004–9015.

40. Yang, J.J.; Wang, Y.T.; Cheng, P.C.; Kuo, Y.J.; Huang, R.C. Cholinergic modulation of neuronal excitability in the rat suprachiasmatic nucleus. *J. Neurophysiol.* 2010, 103, 1397–1409.

41. Corringer, P.J.; Bertrand, S.; Galzi, J.L.; Devillers-Thiery, A.; Changeux, J.P.; Bertrand, D. Mutational analysis of the charge selectivity filter of the α7 nicotinic acetylcholine receptor. *Neuron* 1999, 22, 831–843.

42. Doley, R.; Kini, R.M. Protein complexes in snake venom. *Cell. Mol. Life Sci.* 2009, 66, 2851–2871.

43. Gurnaney, H.; Brown, A.; Litman, R.S. Malignant hyperthermia and muscular dystrophies. *Anesth. Anal.* 2009, 109, 1043–1048.

44. Langeron, O.; Birenbaum, A.; Amour, J. Airway management in trauma. *Minerva Anestesiol.* 2009, 75, 307–311.

45. Gatke, M.R.; Bundgaard, J.R.; Vibe-Mogensen, J. Two novel mutations in the BChE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. *Pharmacogenet. Genomics* 2007, 17, 995–999.

46. Leiser, S.C.; Bowlby, M.R.; Comery, T.A.; Dunlop, J. A cog in cognition: How the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. *Pharmacol. Ther.* 2009, 122, 302–311.

47. Soderman, A.; Mikkelsen, J.D.; West, M.J.; Christensen, D.Z.; Jensen, M.S. Activation of nicotinic α(7) acetylcholine receptor enhances long term potentiation in wild type mice but not in APP (swe)/PS1ΔE9 mice. *Neurosci. Lett.* 2011, 487, 325–329.

48. Thomsen, M.S.; Hansen, H.H.; Timmerman, D.B.; Kikkelsen, J.D. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: From animal models to human pathophysiology. *Curr. Pharm. Des.* 2010, 16, 323–343.

49. Feher, A.; Juhasz, A.; Rimanoczy, A.; Csibri, E.; Kalman, J.; Janka, Z. Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. *Dement. Geriatr. Cogn. Disord.* 2009, 28, 56–62.

50. Chu, L.W.; Ma, E.S.; Lam, K.K.; Chan, M.F.; Lee, D.H. Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer’s disease patients. *Dement. Geriatr. Cogn. Disord.* 2005, 19, 106–112.

51. Tregellas, J.R.; Tanabe, J.; Rojas, D.C.; Shatti, S.; Olincy, A.; Johnson, L.; Martin, L.F.; Soti, F.; Kem, W.R.; Leonard, S.; et al. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. *Biol. Psychiatry* 2011, 69, 7–11.
52. Livingston, P.D.; Srinivasan, J.; Kew, J.N.; Dawson, L.A.; Gotti, C.; Moretti, M.; Shaib, M.; Wonnacott, S. Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. *Eur. J. Neurosci.* **2009**, *29*, 539–550.

53. Martin, L.F.; Kem, W.R.; Freedman, R. Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. *Psychopharmacology* **2004**, *174*, 54–64.

54. Picciotto, M.R.; Caldarone, B.J.; Brunzell, D.H.; Zachariou, V.; Stevens, T.R.; King, S.L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: Physiological and behavioral phenotypes and possible clinical implications. *Pharmacol. Ther.* **2001**, *92*, 89–108.

55. Dziewczapolski, G.; Glogowski, C.M.; Masliah, E.; Heinemann, S.F. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease. *J. Neurosci.* **2009**, *29*, 8805–8815.

56. Lester, H.A.; Fonck, C.; Tapper, A.R.; McKinney, S.; Damaj, M.I.; Balogh, S.; Owens, J.; Wehner, J.M.; Collins, A.C.; Labarca, C. Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action. *Curr. Opin. Drug Discov. Devel.* **2003**, *6*, 633–639.

57. Tracey, K.J. The inflammatory reflex. *Nature* **2002**, *420*, 853–859.

58. Borovikova, L.V.; Ivanova, S.; Zhang, M.; Yang, H.; Botchkina, G.I.; Watkins, L.R.; Wang, H.; Abumrad, N.; Eaton, J.W.; Tracey, K.J. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* **2000**, *405*, 458–462.

59. Tracey, K.J. Reflex control of immunity. *Nat. Rev. Immunol.* **2009**, *9*, 418–428.

60. Tracey, K.J. Fat meets the cholinergic antiinflammatory pathway. *J. Exp. Med.* **2005**, *202*, 1071–1021.

61. Casserly, B.; Baram, M.; Walsh, P.; Sucov, A.; Ward, N.S. Levy, M.M. Implementing a collaborative protocol in a sepsis intervention program: Lessons learned. *Lung* **2011**, *189*, 11–19.

62. Babaev, V.R.; Patel, M.B.; Semenkovich, C.F.; Fazio, S.; Linton, M.F. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. *J. Biol. Chem.* **2000**, *275*, 26293–26299.

63. Herbein, G.; Gras, G.; Khan, K.A.; Abbas, W. Macrophage signaling in HIV-1 infection. *Retrovirology* **2010**, *7*, 34:1–34:13.

64. Pohanka, M.; Snopkova, S.; Havlickova, K.; Bostik, P.; Sinkorova, Z.; Fusek, J.; Kuca, K.; Pikula, J. Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway. *Curr. Med. Chem.* **2011**, *18*, 539–551.

65. Parrish, W.R.; Gallowitsch-Puerta, M.; Czura, C.J.; Tracey, K.J. Experimental therapeutic strategies for severe sepsis: Mediators and mechanisms. *Ann. N. Y. Acad. Sci.* **2008**, *1144*, 210–236.

66. Xiong, J.; Xue, F.S.; Yuan, Y.J.; Wang, Q.; Liao, X.; Wang, W.L. Cholinergic anti-inflammatory pathway: A possible approach to protect against myocardial ischemia reperfusion injury. *Chin. Med. J. (Engl.)* **2010**, *123*, 2720–2726.

67. Zhou, Y.; Zuo, X.; Li, Y.; Wang, Y.; Zhao, H.; Xiao, X. Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. *Rheumatol. Int.* **2012**, *32*, 97–104.

68. Azam, L.; McIntosh, J.M. Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. *Acta Pharmacol. Sin.* **2009**, *30*, 771–783.
69. Millard, E.L.; Daly, N.L.; Craik, D.J. Structure-activity relationships of alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors. *Eur. J. Biochem.* 2004, 271, 2320–2326.

70. Favreau, P.; Krimm, I.; Le Gall, F.; Bobenrieth, M.J.; Lamthan, H.; Bouet, F.; Servent, D.; Molgo, J.; Menez, A.; Letouneux, Y.; et al. Biochemical characterization and nuclear magnetic resonance structure of novel alpha-conotoxins isolated from the venom of conus consors. *Biochemistry* 1999, 38, 6317–6326.

71. Hogg, R.C.; Miranda, L.P.; Craik, D.J.; Lewis, R.J.; Alewood, P.F.; Adams, D.J. Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor. *J. Biol. Chem.* 1999, 274, 36559–36564.

72. Dutertre, S.; Nicke, A.; Lewis, R.J. Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylcholine receptor. *J. Biol. Chem.* 2005, 280, 30460–30468.

73. Blanchfield, J.T.; Gallagher, O.P.; Cros, C.; Lewis, R.J.; Alewood, P.F.; Toth, I. Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue. *Biochem. Biophys. Res. Commun.* 2007, 361, 97–102.

74. Whiteaker, P.; McIntosh, J.M.; Luo, S.; Collins, A.C.; Marks, M.J. 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. *Mol. Pharmacol.* 2000, 57, 913–925.

75. Arias, H.R. Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors. *Neurochem. Int.* 2000, 36, 595–645.

76. McCann, C.M.; Bracamontes, J.; Steinbach, J.H.; Sanes, J.R. The cholinergic antagonist alpha-bungarotoxin also binds and blocks a subset of GABA receptors. *Proc. Natl. Acad. Sci. USA* 2006, 103, 5149–5154.

77. Chang, C.C. Looking back on the discovery of alpha-bungarotoxin. *J. Biomed. Sci.* 1999, 6, 368–375.

78. Hawgood, B.J. Professor Chen-Yuan Lee, MD (1915–2001), pharmacologist: Snake venom research at the Institute of Pharmacology, National Taiwan University. *Toxicon* 2002, 40, 1065–1072.

79. Chu, N.S. Contribution of a snake venom toxin to myasthenia gravis: The discovery of alpha-bungarotoxin in Taiwan. *J. Hist. Neurosci.* 2005, 14, 138–148.

80. Aracava, Y.; Pereira, E.F.; Maelicke, A.; Albuquerque, E.X. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons. *J. Pharmacol. Exp. Ther.* 2005, 312, 1195–1205.

81. Banerjee, P.; Samoriski, G.; Gupta, S. Comments on “Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons”. *J. Pharmacol. Exp. Ther.* 2005, 313, 928–929.

82. Taly, A.; Corringer, P.J.; Guedin, D.; Lestage, P.; Changeux, J.P. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system. *Nat. Rev. Drug Discov.* 2009, 8, 733–750.

83. Santos, M.D.; Alkondon, M.; Pereira, E.F.; Aracava, Y.; Eisenberg, H.M.; Maelicke, A.; Albuquerque, E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. *Mol. Pharmacol.* 2002, 61, 1222–1234.
84. Schedel, A.; Thornton, S.; Schloss, P.; Kluter, H.; Bugert, P. Human platelets express functional alpha 7-nicotinic acetylcholine receptors. *Arterioscler. Thromb. Vasc. Biol.* **2011**, *31*, 928–934.

85. Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. *J. Toxicol. Clin. Toxicol.* **2002**, *40*, 803–816.

86. Pohanka, M.; Jun, D.; Kuca, K. Amperometric biosensor for evaluation of competitive cholinesterase inhibition by the reactivation HI-6. *Anal. Lett.* **2007**, *40*, 2351–2359.

87. Soukup, O.; Pohanka, M.; Tobin, G.; Jun, D.; Fusek, J.; Musilek, K.; Marek, J.; Kassa, J.; Kuca, K. The effect of HI-6 on cholinesterases and on the cholinergic system of the rat bladder. *Neuroendocrinol. Lett.* **2008**, *29*, 759–762.

88. Pohanka, M.; Pavlis, O.; Pikula, J.; Treml, F.; Kuca, K. Modulation of tularemia disease progress by the bisquaternary pyridinium oxime HI-6. *Acta Vet. (Brno)* **2010**, *79*, 443–448.

89. Pohanka, M.; Pejchal, J.; Horackova, S.; Kuca, K.; Bandouchova, H.; Damkova, V.; Pikula, J. Modulation of ionising radiation generated oxidative stress by HI-6 (asoxime) in a laboratory rat model. *Neuroendocrinol. Lett.* **2010**, *31*, 62–68.

90. Tsuji, A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport system. *NeuroRx* **2005**, *2*, 54–62.

91. Liu, X.; Testa, B.; Fahr, A. Lipophilicity and its relationship with passive drug permeation. *Pharm. Res.* **2011**, *28*, 962–977.

92. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport system to the blood-brain barrier as a supporting and protecting interface for the brain, importance for CNS drug discovery and development. *Pharm. Res.* **2007**, *24*, 1745–1758.

93. Wallace, T.L.; Callahan, P.M.; Tehim, A.; Bertrand, D.; Tombaugh, G.; Wang, S.; Xie, W.; Rowe, W.B.; Ong, V.; Graham, E.; *et al.* RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. *J. Pharmacol. Exp. Ther.* **2011**, *336*, 242–253.

94. Chiron, C.; Haydar, S.N.; Aschmies, S.; Bothmann, H.; Castaldo, C.; Cocconcelli, G.; Comery, T.A.; Di, L.; Dunlop, J.; Lock, T.; *et al.* Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: Identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914). *J. Med. Chem.* **2010**, *53*, 4379–7389.

95. Roncarati, R.; Scali, C.; Comery, T.A.; Grauer, S.M.; Aschmi, S.; Bothmann, H.; Jow, B.; Kowal, D.; Gianfriddo, M.; Kelley, C.; *et al.* Procognitive and neuroprotective activity of novel alpha 7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. *J. Pharmacol. Exp. Ther.* **2009**, *329*, 459–468.

96. Malysz, J.; Anderson, D.J.; Gronlien, J.H.; Ji, J.; Bunnelle, W.H.; Hakerud, M.; Thorin-Hagene, K.; Ween, H.; Helfrich, R.; Hu, M.; *et al.* *In vitro* pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. *J. Pharmacol. Exp. Ther.* **2010**, *334*, 863–874.

97. Asenjo Lobos, C.; Komossa, K.; Rummel-Kluge, C.; Hunger, H.; Schmid, F.; Schwarz, S.; Leucht, S. Clozapine versus other atypical antipsychotics for schizophrenia. *Cochrane Database Syst. Rev.* **2010**, *83*, doi:10.1002/14651858.CD006633.
98. Bertrand, D.; Gopalakrishnan, M. Allosteric modulation of nicotinic acetylcholine receptors. *Biochem. Pharmacol.* 2007, 74, 1155–1163.

99. Kalappa, B.I.; Gusev, A.G.; Uteshev, V.V. Activation of functional α7-containing nAChRs in hippocampal CA1 pyramidal neurons by physiologica levels of choline in the presence of PNU-120596. *PLoS One* 2010, 5, doi:10.1371/journal.pone.0013964.

100. Lippiello, P.M.; Beaver, J.S.; Gatto, G.J.; James, J.W.; Jordan, K.G.; Traina, V.M.; Xie, J.; Benchrif, M. TC-5214 (S-(+)-mecamylamine): A neuronal nicotinic receptor modulator with antidepressant activity. *CNS Neurosci. Ther.* 2008, 14, 266–277.

101. Sydserff, S.; Sutton, E.J.; Song, D.; Quirk, M.C.; Maciag, C.; Li, C.; Jonak, G.; Gurley, D.; Gordon, J.C.; Christian, E.P.; et al. Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. *Biochem. Pharmacol.* 2009, 78, 880–888.

102. Hauser, T.A.; Kucinski, A.; Jordan, K.G.; Gatto, G.J.; Wersinger, S.R.; Hesse, R.A.; Stachowiak, E.K.; Stachowiak, M.K.; Papke, R.L.; Lippiello, P.M.; et al. TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. *Biochem. Pharmacol.* 2009, 78, 803–812.

103. Jonnala, R.R.; Graham, J.H.; Terry, A.V.; Beach, J.W.; Young, J.A.; Buccafusco, J.J. Relative level of cytoprotection produced by analogs of choline and the role of alpha 7-nicotinic acetylcholine receptors. *Synapse* 2003, 47, 262–269.

104. Pohanka, M. Cholinesterases, a target of pharmacology and toxicology. *Biomed. Pap. Olomouc* 2011, 155, 219–223.

105. Minutoli, L.; Squadrito, F.; Nicotina, P.A.; Giuliani, D.; Ottani, A.; Polito, F.; Bitto, A.; Irrera, N.; Guzzo, G.; Spaccapelo, L.; et al. Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. *Crit. Care Med.* 2011, 39, 1089–1096.

106. Rosas-Ballina, M.; Tracey, K.J. Cholinergic control of inflammation. *J. Intern. Med.* 2009, 265, 663–679.

107. Rosas-Ballina, M.; Goldstein, R.S.; Gallowitsch-Puerta, M.; Yang, L.; Valdes-Ferrer, S.I.; Patel, N.B.; Chavan, S.; Al-Abed, Y.; Yang, H.; Tracey, K.J. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. *Mol. Med.* 2009, 15, 195–202.

108. Pavlov, V.A.; Ochani, M.; Yang, L.H.; Gallowitsch-Puerta, M.; Ochani, K.; Lin, X.; Levi, J.; Parrish, W.R.; Rosas-Ballina, M.; Czura, C.J.; et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. *Crit. Care Med.* 2007, 35, 1139–1144.

109. Kox, M.; Pompe, J.C.; Peters, E.; VAneker, M.; van der Laak, J.W.; van der Hoeven, J.G.; Scheffer, G.J.; Hoedemaekers, C.W.; Pickkers, P. α7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injury. *Br. J. Anaesth.* 2011, 107, 559–566.
110. Tregellas, J.R.; Tanabe, J.; Rojas, D.C.; Shatti, S.; Olincy, A.; Johnson, L.; Martin, L.F.; Soti, F.; Kem, W.R.; Leonard, S.; Freedman, R. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. *Biol. Psychiatry* **2011**, *69*, 7–11.

111. Bowman, G.; Bonneau, R.H.; Chinchilli, V.M.; Tracey, K.J.; Cockroft, K.M. A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. *Neurocrit. Care* **2006**, *5*, 222–229.

112. Oke, S.L.; Tracey, K.J. From CNI-1493 to the immunological homunculus: Physiology of the inflammatory reflex. *J. Leukoc. Biol.* **2008**, *83*, 512–517.

113. Bacher, M.; Dodel, R.; Aljabari, B.; Keyvani, K.; Marambaud, P.; Kayed, R.; Glabe, C.; Goertz, N.; Hoppmann, A.; Sachser, N.; *et al.* CNI-1493 inhibits Abeta production, and cognitive deterioration in an animal model of Alzheimer’s disease. *J. Exp. Med.* **2008**, *205*, 1593–1599.

114. Oettinger, C.W.; D’Souza, M.J. Synergism in survival to endotoxic shock in rats given microencapsulated CNI-1493 and antisense oligomers to NF-kappaB. *J. Microencapsul.* **2010**, *27*, 372–376.

115. Dotan, I.; Rachmilewitz, D.; Schreiber, S.; Eliakim, R.; van der Woude, C.J.; Kornbluth, A.; Buchman, A.L.; Bar-Meir, S.; Bokemeyer, B.; Goldin, E.; *et al.* A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. *Gut* **2010**, *59*, 760–766.

116. The, F.O.; Boeckxstaens, G.E.; Snoek, S.A.; Cash, J.L.; Bennink, R.; Larosa, G.J.; van den Wijngaard, R.M.; Greaves, D.R.; de Jonge, W.J. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. *Gastroenterology* **2007**, *133*, 1219–1228.

117. Van Kampen, M.; Selbach, K.; Schneider, R.; Schiegel, E.; Boess, F.; Schreiber, R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. *Psychopharmacology* **2004**, *172*, 375–383.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).